1. DIYTechnicalAnalysis is a private community of traders and investors interested in building wealth from Indian equity market. You can become a member with a one time registration fee of ₹199. Click here to become a member

Natco Pharma

Discussion in 'Fundamental Analysis' started by chaitanya_mella, Aug 13, 2018.

  1. chaitanya_mella

    chaitanya_mella Contributor

    Joined:
    May 20, 2017
    Messages:
    141
    Likes Received:
    109
    Natco pharma manufactures drugs for cancer and hepatitis c. The market for these is ever growing and looks like it has huge potential. Recent quarter took a hit due to fall in market size of hepatitis c. The company has setup R&D for cardiology and diabetes. And looking to increase revenues from India and Rest of the world (other than USA)

    As per their 2016-2017 annual report their EBIDTA has grown at CAGR of roughly 40 percent for 5 years. Average ROE over last 10 years is just over 20. Operating profit margin has been around 25% average over the decade.

    Any thoughts on current price being good to enter?


    Sent from my iPhone using DIY Technical Analysis mobile app
     
    chaitanya_mella, Aug 13, 2018
    Share #1
    nirajshah likes this.
  2. shabbir

    shabbir Administrator Staff Member

    Joined:
    Apr 30, 2012
    Messages:
    6,702
    Likes Received:
    1,940
    Looks quite impressive.
     
    shabbir, Aug 14, 2018
    Share #2
    nirajshah and chaitanya_mella like this.
  3. chaitanya_mella

    chaitanya_mella Contributor

    Joined:
    May 20, 2017
    Messages:
    141
    Likes Received:
    109
    They target difficult medicines like cancer drugs and Hep C drugs giving them an edge. And they drive business through managing partners who take care of litigation if needed. Probably provides some insulation from external shocks.
     
    chaitanya_mella, Aug 14, 2018
    Share #3
    nirajshah and shabbir like this.
  4. rahul_majumdar

    rahul_majumdar Member

    Joined:
    Jul 30, 2018
    Messages:
    10
    Likes Received:
    10
    Good balanced company with the appetite to think big. Can be considered as portfolio stock for long term capital appreciation.
     
    rahul_majumdar, Aug 14, 2018
    Share #4
    nirajshah, shabbir and chaitanya_mella like this.
  5. avrajq

    avrajq Member

    Joined:
    Apr 8, 2018
    Messages:
    12
    Likes Received:
    12
    The stock has corrected and is now below its 50 and 200 SMA. However, the correction from around 850 to current level (nearing 750) has been on relatively lower volumes, suggesting that the bottom may be near - say - around 700 or so. There's no indication now that the correction is over. One may wait and watch for signs of recovery around that level.
     
    avrajq, Aug 14, 2018
    Share #5
    nirajshah, shabbir and chaitanya_mella like this.
  6. bhat64

    bhat64 Apprentice

    Joined:
    Oct 27, 2016
    Messages:
    230
    Likes Received:
    249
    Natco is a good niche in Pharma sector with exceptional return ratios. I would start chewing more of it from now as it begins stabilise at current price. Natco is the only Pharma company apart from Jenburkt whose chart is different than rest of the Pharma stocks. It didn’t go into major downtrend


    Sent from my iPhone using DIY Technical Analysis mobile app
     
    bhat64, Aug 26, 2018
    Share #6
    shabbir, nirajshah and chaitanya_mella like this.
  7. nirajshah

    nirajshah Champion

    Joined:
    Aug 17, 2016
    Messages:
    546
    Likes Received:
    302
    nirajshah, Aug 29, 2018
    Share #7
    shabbir likes this.